Initiator Pharma Management

Management Kriterienprüfungen 2/4

Initiator Pharma's CEO ist Claus Olesen , ernannt in May 2016, hat eine Amtszeit von 8.08 Jahren. besitzt direkt 4.3% der Aktien des Unternehmens, im Wert von SEK23.20M . Die durchschnittliche Betriebszugehörigkeit des Managementteams und des Verwaltungsrats beträgt 8.3 Jahre bzw. 5.6 Jahre.

Wichtige Informationen

Claus Olesen

Geschäftsführender

n/a

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts	n/a
Amtszeit als Geschäftsführer	8.1yrs
Eigentum des Geschäftsführers	4.3%
Durchschnittliche Amtszeit des Managements	8.3yrs
Durchschnittliche Amtszeit der Vorstandsmitglieder	5.6yrs

Jüngste Management Updates

Recent updates

Geschäftsführer

Claus Olesen (50 yo)

8.1yrs

Amtszeit

Dr. Claus Elsborg Olesen is Chief Executive Officer at Stipe Therapeutics. He serves Chief Executive Officer at Initiator Pharma A/S since May 02, 2016 and serves as its Director since September 19, 2016 a...

Führungsteam

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Claus Olesen	Co-Founder	8.1yrs	keine Daten	4.3% DKK 22.3m
Dan Peters	Co-Founder & CTO	8.4yrs	keine Daten	keine Daten
Ulf Simonsen	Co-Founder	no data	keine Daten	1.23% DKK 6.4m
Mikael Thomsen	Co-Founder & Chief Development Officer	no data	keine Daten	1.42% DKK 7.4m
Torgeir Vaage	Chief Financial Officer	8.4yrs	keine Daten	keine Daten
Allan Wehnert	Senior Vice President of Clinical and R&D Strategy & Portfolio Management	3.5yrs	keine Daten	keine Daten
Susanne Thomsen	Head of Clin Ops	no data	keine Daten	keine Daten
Rene Egebro	Head of CMC	no data	keine Daten	keine Daten

8.3yrs

Durchschnittliche Betriebszugehörigkeit

60yo

Durchschnittliches Alter

Erfahrenes Management: INITDas Führungsteam des Unternehmens verfügt über eine langjährige Erfahrung (8.3 ).

Vorstandsmitglieder

Name	Position	Amtszeit	Vergütung	Eigentümerschaft
Claus Olesen	Co-Founder	7.8yrs	keine Daten	4.3% DKK 22.3m
Gunnar Magnus Severus Persson	Chairman of the Board of Directors	7.8yrs	keine Daten	0.50% DKK 2.6m
Henrik Moltke	Director	7.8yrs	keine Daten	0.26% DKK 1.4m
Irwin Goldstein	Member of Scientific & Clinical Advisory Board	3.5yrs	keine Daten	keine Daten
Gunilla Ekstrom	Independent Director	1.7yrs	keine Daten	0.036% DKK 186.2k
Annette Colin	Director	3.4yrs	keine Daten	0.75% DKK 3.9m
Peter Holm	Director	7.8yrs	keine Daten	keine Daten
Sue Goldstein	Member of Scientific & Clinical Advisory Board	3.5yrs	keine Daten	keine Daten

5.6yrs

Durchschnittliche Betriebszugehörigkeit

61.5yo

Durchschnittliches Alter

Erfahrener Vorstand: INITDie Vorstandsmitglieder gelten als erfahren (5.6 Jahre durchschnittliche Amtszeit).

Initiator Pharma Management

Management Kriterienprüfungen 2/4

Wichtige Informationen

Jüngste Management Updates

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

No independent directors

No independent directors

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Announces Management Changes

Recent updates

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

Health Check: How Prudently Does Initiator Pharma (STO:INIT) Use Debt?

New minor risk - Shareholder dilution

Initiator Pharma A/S to Report Fiscal Year 2023 Final Results between Apr 29, 2024 and May 03, 2024

Initiator Pharma A/S Expands Its Position to Broader Sexual Health Franchise and Intends Business Development Efforts

Initiator Pharma A/S to Report Q1, 2024 Results on May 10, 2024

Initiator Pharma A/S, Annual General Meeting, May 24, 2024

New minor risk - Share price stability

Initiator Pharma A/S Announces Indication Expansion - Clinical Drug Candidates Active in Models of Female Sexual Dysfunction

New minor risk - Financial position

Initiator Pharma A/S Announces Positive Results from Pudafensine Phase I Pharmacokinetic Trial

Initiator Pharma A/S Completes Recruitment in Phase IIb Trial with Pudafensine (IP2015)

Initiator Pharma A/S Reports Dose-Dose-Dose-dependent Significant Erectile Dysfunction of IP 2018 in the Placebo-Controlled Phase IIa Clinical Trial of Erectile Dysfunction

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Forecast breakeven date pushed back to 2024

Initiator Pharma A/S to Report Fiscal Year 2022 Results on May 01, 2023

Is Initiator Pharma (STO:INIT) Using Debt In A Risky Way?

Initiator Pharma A/S, Annual General Meeting, May 26, 2023

Initiator Pharma A/S Ready to Start Phase I Pharmacokinetics Study for New IP2015 Formulations

No independent directors

Initiator Pharma A/S Provides an Update on Its Clinical Programs

Initiator Pharma A/S Reports the Final Analysis of Positive Efficacy Data from the IPTN2021 Program Phase I Study

Initiator Pharma A/S has completed a Follow-on Equity Offering in the amount of SEK 2.499998 million.

Initiator Pharma A/S Reports Positive Efficacy Data Outcome of the Iptn2021 Program Phase I Study to Assess Pain-Reducing Effects

No independent directors

Initiator Pharma A/S announced that it expects to receive SEK 19.999995 million in funding from Adrigo Asset Management AB, Linc AB

Initiator Pharma A/S Signs Option Agreement for Late-Stage Drug Candidate

Initiator Pharma A/S Appoints Christina Guldberg as Senior Director, Clinical Development and Outcomes Research, Effective on March 1, 2022

Initiator Pharma A/S Initiates Dosing in the IPTN2021 Program Phase I Study to Assess Pain Reducing Effects

Initiator Pharma A/S Announces an Update on its Clinical Programs

Initiator Pharma A/S Receives CTA Approval for Iptn2021 Program Phase I Study to Assess Pain Reducing Effects

We're Not Worried About Initiator Pharma's (STO:INIT) Cash Burn

Initiator Pharma Includes the First Patient in Phase 2B Study with Iped2015 in Erectile Dysfunction Patients

We're Not Very Worried About Initiator Pharma's (NGM:INIT) Cash Burn Rate

Initiator Pharma Receives Approval for Phase 2a Study with IP2018

Forecast to breakeven in 2023

Initiator Pharma A/S Files its Clinical Trial Application for its Planned Phase II Study in Erectile Dysfunction Patients with IPED2015

New 90-day high: kr5.58

New 90-day low: kr4.18

Initiator Pharma A/S to Report Q3, 2021 Results on Nov 19, 2021

Initiator Pharma A/S to Report First Half, 2021 Results on Aug 20, 2021

Initiator Pharma A/S Announces Management Changes

Initiator Pharma A/S announces First patient dosed in Phase 2a trial with IP2018

Initiator Pharma A/S announced that it expects to receive SEK 23 million in funding from MAC Clinical Research Ltd

Initiator Pharma Secures Funding for IPED2015 clinical Phase 2b study

New 90-day low: kr4.69

New 90-day low: kr4.99

Initiator Pharma A/S has completed a Composite Units Offering.

Geschäftsführer

Amtszeit

Führungsteam

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter

Vorstandsmitglieder

Durchschnittliche Betriebszugehörigkeit

Durchschnittliches Alter